How RSV vaccine protection differs across communities
Predicting and monitoring variations in the effects of vaccines against RSV
This project will compare how well different RSV prevention options protect infants, older adults, and communities using U.S. health records.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11057081 on NIH RePORTER |
What this research studies
We will use routinely collected U.S. healthcare and administrative records to map where RSV causes the most illness and how that varies by age and socioeconomic group. The team will apply statistical and Bayesian models to track differences in outpatient and severe cases and to predict how vaccines and long‑acting antibodies will change disease patterns. They will generate timely estimates of effectiveness and safety as new prevention options are rolled out and look for disparities in impact. Findings will be shared to help guide which delivery strategies may work best in different places and populations.
Who could benefit from this research
Good fit: This project does not enroll individuals but is most relevant to parents of infants, caregivers, and older adults who receive or consider RSV vaccines or antibody protection.
Not a fit: People outside the United States or those without records in the analyzed U.S. databases are unlikely to be included and may not directly benefit from these results.
Why it matters
Potential benefit: If successful, this work could help health systems choose prevention strategies that better protect infants and older adults and reduce inequities in RSV burden.
How similar studies have performed: Clinical trials of RSV vaccines and long‑acting antibodies have shown benefit, and this project builds on prior successful modeling of RSV patterns to apply those methods at finer geographic and socioeconomic scales.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Weinberger, Daniel Martin — Yale University
- Study coordinator: Weinberger, Daniel Martin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.